The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments.
Oellerich
Michael
M
Abteilung Klinische Chemie, Georg-August-University Göttingen, Germany. moeller@med.uni-goettingen.de
Armstrong
Victor W
VW
D016572:Cyclosporine / Q000493:pharmacokinetics; D016903:Drug Monitoring; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000493:pharmacokinetics; D016377:Organ Transplantation; D011494:Protein Kinases / Q000378:metabolism; D020123:Sirolimus / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D058570:TOR Serine-Threonine Kinases; D016559:Tacrolimus / Q000493:pharmacokinetics
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus